nach oben

Current Diabetes Reports

Erschienen in:

01.11.2018 | Macrovascular Complications in Diabetes (VR Aroda and A Getaneh, Section Editors)

Beyond Statins: Who and When to Prescribe?

verfasst von: Om Ganda

Erschienen in: Current Diabetes Reports | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Statins are the most evidence-based therapy to target LDL-C to reduce atherosclerotic events. Yet, many people are unable to achieve adequate reduction in this key atherogenic factor. Moreover, residual risk of cardiovascular events may persist even after “optimal” LDL-C due to elevations in triglyceride-rich lipoproteins. Therefore, additional therapies beyond statins are needed, particularly in patients with diabetes.

Recent Findings

Clinical trials with ezetimibe and PCSK9 inhibitors have reported further reductions in cardiovascular events, beyond statins. The latter are particularly effective in lowering LDL-cholesterol and in reducing event rates. However, they are not effective in lowering triglycerides. Currently available fibrates and niacin have not proven effective in combination with statins in clinical trials, while the top line results of the REDUCE-IT trial with EPA, a pure omega-3 fatty acid, reporting 25% relative risk reduction in primary endpoints are of great interest.

Summary

Recently approved agents have the promise to improve cardiovascular outcomes beyond statins. Many novel drugs in development have the potential to further improve prognosis.

Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370(16):1514–23.CrossRef

• Burrows NR, Li Y, Gregg EW, Geiss LS. Declining rates of hospitalization for selected cardiovascular disease conditions among adults aged ≥ 35 years with diagnosed diabetes, U.S., 1998–2014. Diabetes Care. 2018;41(2):293–302. A recent analysis of improved prognosis of patients with cardiovascular complications; yet a reminder of persistently high prevalence of CV complications, particularly heart failure. CrossRef

Gregg EW, Cheng YJ, Srinivasan M, Lin J, Geiss LS, Albright AL, et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet. 2018;391(10138):2430–40.CrossRef

Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105–13.

Prospective Studies Collaboration and Asia Pacific Cohort Studies Collaboration. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. Lancet Diabetes Endocrinol. 2018;6(7):538–46.CrossRef

Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson A-M, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407–18.CrossRef

•• Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44. An extensive case-control study of a large cohort of patients with type 2 diabetes, providing evidence for almost complete abrogation of increased cardiovascular events and mortality by control of all five major risk factors to target range. CrossRef

Huxley RR, Peters SA, Mishra GD, Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(3):198–206.CrossRef

de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014;130(13):1110–30.CrossRef

10.

Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.CrossRef

11.

Collaboration CTTC, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.CrossRef

12.

Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;2013

13.

• Hong KN, Fuster V, Rosenson RS, Rosendorff C, Bhatt DL. How low to go with glucose, cholesterol, and blood pressure in primary prevention of CVD. JACC. 2017a;70(17):2171–85. This review provides the current state of consensus and controversy regarding the optimal goals for glcemic, lipid, and blood pressure goals. CrossRef

14.

Ganda OP, Mitri J. Current consensus and controversies in guidelines for lipid and hypertension management in diabetes. Curr Cardiol Rep. 2016;18(11):114.CrossRef

15.

DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6(4):400–8.CrossRef

16.

Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of Atherogenic lipoproteins and the risk for cardiovascular events. A meta-analysis of statin trials. JACC. 2014;64(5):485–94.

17.

Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocr Pract. 2017;23(Suppl 2):1–87.CrossRef

18.

Zhang H, Plutzky J, Ge W, Shubina M, Turchin A. Predictors of a successful statin reattempt after an adverse reaction. J Clin Lipidol. 2018;12(3):643–51.CrossRef

19.

Zhang H, Plutzky J, Shubina M, Turchin A. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med. 2017;167(4):221–7.CrossRef

20.

•• Nissen SE. Statin intolerance: an elusive but morbid disorder. J Am Coll Cardiol. 2017;69(11):1396–8. This editorial summarizes objective evidence for statin intolerance based on various studies and the need to address this issue and options to reduce CV risk in such patients. CrossRef

21.

•• Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. JACC. 2018a;72(3):330–43. A recent state of the art review describing residual risk despite optimal LDL-C management based on genetic, epidemiologic, and clinical trial evidence and how to address this issue in clinical management. CrossRef

22.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.CrossRef

23.

•• Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571–82. The subgroup analysis of the IMPROVE-IT trial ( ref no. 22), describing the differences in outcomes in the pre-specified, diabetes cohort, compared to those with pre-diabetes or normal glucose. Patients with diabetes had markedly superior outcome, compared to non-diabetics. CrossRef

24.

Ganda OP, Garg A. Dyslipidemias Pathophysiology, Evaluation and Management. Contemporary Endocrinology. In: Garg A, editor. Bile acid sequestrants: role in treating dyslipidemias and risk-benefits. New York: Humana Press; 2015. p. 453–64.

25.

Preiss D, Mafham M. PCSK9 inhibition: the dawn of a new age in cholesterol lowering? Diabetologia. 2017;60(3):381–9.CrossRef

26.

Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015;132(17):1648–66.CrossRef

27.

•• Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. JACC. 2018;72(3):314–29. The most recent comprehensive review of PCSK 9 biology , pathophysiology, and management issues. CrossRef

28.

Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle MK, Knickelbine T, et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017;6(12).

29.

•• Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017a;376(18):1713–22. A landmark paper descibing the CV outcomes in the first RCT with PCSK 9 inhibitor, evolocumab. CrossRef

30.

Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682–9.CrossRef

31.

Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive function in a randomized trial of Evolocumab. N Engl J Med. 2017a;377(7):633–43.CrossRef

32.

Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017b;390(10106):1962–71.CrossRef

33.

Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017b;5(12):941–50.CrossRef

34.

Ganda OP. Statin-induced diabetes: incidence, mechanisms, and implications. F1000Research. 2016;5.CrossRef

35.

Wang S, Cai R, Yuan Y, Varghese Z, Moorhead J, Ruan XZ. Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis. Sci Rep. 2017;7:39982.CrossRef

36.

•• Maki KC. The ODYSSEY Outcomes trial: clinical implications and exploration of the limits of what can be achieved through lipid lowering. J Clin Lipidol. 2018 Jun 1. pii: S1933–2874(18)30245–9. https://doi.org/10.1016/j.jacl.2018.05.016. A summary of the principal findings of the second RCT with alirocumab, presented at the ACC annual meetings in 2018. CrossRef

37.

Ray KK, Leiter LA, Muller-Wieland D, Cariou B, Colhoun HM, Henry RR, et al. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab. 2018;20(6):1479–89.CrossRef

38.

Ganda OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, Koren A, Mandel J, et al. Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. Diabetes Obes Metab. 2018;20 (10): 2389–2398CrossRef

39.

•• Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, De Palma SM, et al. 2017 focused update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785–822. A position statement by the ACC expert panel regarding the risk category and the use of PCSK inhibitors in clinical practice. CrossRef

40.

Orringer CE, Jacobson TA, Saseen JJ, Brown AS, Gotto AM, Ross JL, et al. Update on the use of PCSK9 inhibitors in adults: recommendations from an Expert Panel of the National Lipid Association. J Clin Lipidol. 2017;11(4):880–90.CrossRef

41.

Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430–40.CrossRef

42.

• Superko HR, Zhao X-Q, Hodis HN, Guyton JR. Niacin and heart disease prevention: engraving its tombstone is a mistake. J Clin Lipidol. 2017;11(6):1309–17. A detailed discussion of older and recent angiographic studies and clinical trials with niacin. CrossRef

43.

Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146–57.CrossRef

44.

Blom DJ, Averna MR, Meagher EA, du Toit TH, Sirtori CR, Hegele RA, et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation. 2017;136(3):332–5.CrossRef

45.

Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years’ treatment with lomitapide. JAMA Intern Med. 2014;174(3):443–7.CrossRef

46.

Santos RD, Raal FJ, Donovan JM, Cromwell WC. Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J Clin Lipidol. 2015;9(2):201–9.CrossRef

47.

• Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9(3):295–304. A promising new agent to treat hyperlipidemia , currently in clinical trials. CrossRef

48.

Stein E, Bays H, Koren M, Bakker-Arkema R, Bisgaier C. Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients. J Clin Lipidol. 2016;10(5):1212–22.CrossRef

49.

Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 deficiency and protection against coronary artery disease. JACC. 2017;69(16):2054–63.CrossRef

50.

Taub R, Chiang E, Chabot-Blanchet M, Kelly MJ, Reeves RA, Guertin MC, et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis. 2013;230(2):373–80.CrossRef

51.

Dujovne CA. Red yeast rice preparations: are they suitable substitutions for statins? Am J Med. 2017;130(10):1148–50.CrossRef

52.

Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375(9726):1634–9.CrossRef

53.

Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626–35.CrossRef

54.

Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ Res. 2016;118(4):579–85.CrossRef

55.

Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. JACC. 2008;51(7):724–30.CrossRef

56.

Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the Treating to New Targets (TNT) trial. Circulation. 2018:CIRCULATIONAHA.117.032318.

57.

Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab. 2018;

58.

Toth PP, Granowitz C, Hull M, Liasson D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Amer Heart Assoc. 2018:1–11.

59.

• Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010. The only RCT of a fibrate in combination with statin therapy and cardiovascular outcomes.

60.

Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, et al. Effects of pemafibrate, a novel selective PPARα modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41(3):538–46.CrossRef

61.

• HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12. This and no. 62 are the two RCTs of niacin in combination with statin therapy and cardiovascular outcomes.

62.

• AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67. This and no. 61 are the two RCTs of niacin in combination with statin therapy and cardiovascular outcomes.

63.

Group THTRC. Effects of Anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217–27.CrossRef

64.

•• Sansbury BE, Spite M. Resolution of acute inflammation and the role of resolvins in immunity, thrombosis, and vascular biology. Circ Res. 2016;119(1):113–30. A comprehensive mechanistic review of the role of inflammation and the concepts underlying biology of resolvins in inflammation resolution. CrossRef

65.

•• Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242(1):357–66. A review of molecular basis of anti-atheroscerotic effects of omega-3 fatty acids, with special emphasis on potentially unique benefits of EPA. CrossRef

66.

Sherratt SCR, Mason RP. Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid. Biochem Biophys Res Commun. 2018;496(2):335–8.CrossRef

67.

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: Meta-analysis of 10 trials involving 77 917 individuals. JAMA cardiology. 2018;3:225–34.CrossRef

68.

Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif J-C, et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Clin Cardiol. 2017;40(3):138–48.CrossRef

69.

•• REDUCE-IT™ CARDIOVASCULAR OUTCOMES STUDY OF VASCEPA® (ICOSAPENT ETHYL) CAPSULES MET PRIMARY ENDPOINT. https://investor.amarincorp.com/news-releases/news-release-details/reduce-ittm-cardiovascular-outcomes-study-vascepar-icosapent. Accessed 24 Sept 2018. Topline results of the highly significant cardiovascular outcomes from the long-term, multicenter trial, REDUCE-IT

70.

Ascend Study Collaborative Group. Effects of n-3fatty acid supplements in diabetes mellitus. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1804989

71.

TG T, HDL Working Group of the Exome Sequencing Project NH, Lung, Institute B. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014;371(1):22–31.

72.

Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32–41.CrossRef

73.

Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438–47.CrossRef

74.

• Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by Volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39(8):1408–15. A study of the metabolic effects of a promising novel agent for intensive treatment in severe hypertriglyceridemia. CrossRef

75.

Olshan DS, Rader DJ. Angiopoietin-like protein 4: a therapeutic target for triglycerides and coronary disease? J Clin Lipidol. 2018.

76.

Dewey FE, Gusarova V, Dunbar RL, O’Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211–21.CrossRef

77.

Dewey FE, Gusarova V, O’Dushlaine C, Gottesman O, Trejos J, Hunt C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123–33.CrossRef

78.

Khera AV, Won HH, Peloso GM, O'Dushlaine C, Liu D, Stitziel NO, et al. Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease. JAMA. 2017;317(9):937–46.CrossRef

79.

Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200–6.CrossRef

80.

Khunti K, Ceriello A, Cos X, De Block C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2018;137:137–48.CrossRef

Titel: Beyond Statins: Who and When to Prescribe?
verfasst von: Om Ganda
Publikationsdatum: 01.11.2018
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 11/2018
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-018-1087-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Beyond Statins: Who and When to Prescribe?

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

App-Based Insulin Calculators: Current and Future State

Glycemic Outcomes of Islet Autotransplantation

Red Meat Consumption (Heme Iron Intake) and Risk for Diabetes and Comorbidities?

Ketosis-Prone Diabetes (Flatbush Diabetes): an Emerging Worldwide Clinically Important Entity

Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial

Lifestyle Factors Affecting the Gut Microbiota’s Relationship with Type 1 Diabetes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin